Previous close | 562.95 |
Open | 586.48 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 578.53 - 587.85 |
52-week range | 336.03 - 661.60 |
Volume | |
Avg. volume | 282 |
Market cap | 43.22B |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | 59.39 |
EPS (TTM) | 9.80 |
Earnings date | 25 July 2024 |
Forward dividend & yield | 4.57 (0.81%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
Despite a net loss, MRVI showcases strategic expansions and robust partnerships, setting the stage for future growth.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
Lonza Group ( VTX:LONN ) Full Year 2023 Results Key Financial Results Revenue: CHF6.72b (up 7.9% from FY 2022). Net...